Compositions comprising avenanthramide C for inducing differentiation of mesenchymal stem cells into chondrocytes and methods of use thereof

The combined use of avocado anthraquinone C (Avn C) and chondroitin sulfate (CS) solved the problem of the effectiveness of MSC differentiation into chondrocytes, and significantly improved the chondrocyte differentiation efficiency. In particular, by regulating key chondrogenic factors and transcription factors, highly efficient chondrocyte differentiation was achieved.

CN122122289APending Publication Date: 2026-05-29MEIZE ASSET MANAGEMENT CO LTD
1 Cites 0 Cited by

Patent Information

Application Number
CN202380103565.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-10-30
Publication Date
2026-05-29

AI Technical Summary

Technical Problem

Existing methods for differentiating mesenchymal stem cells (MSCs) into chondrocytes lack effectiveness, and better inducing agents are needed to improve chondrocyte differentiation efficiency.

Method used

A combination of avocado anthraquinone C (Avn C) and chondroitin sulfate (CS), with concentrations ranging from 10 nM to 50 µM and 300–700 µg/mL of Avn C and CS, was used as a highly efficient factor to promote the differentiation of MSCs into chondrocytes by regulating the expression of key chondrogenic extracellular matrix factors and transcription factors.

Benefits of technology

It significantly enhances the differentiation capacity of MSCs into chondrocytes by upregulating the expression of type II collagen (COL2A1) and enhancing the transcriptional activity of SOX9, thereby promoting the expression and functional secretion of chondrocyte markers and providing a more efficient chondrocyte differentiation pathway.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention discloses application of avenanthramide C (Avn C) as an inducer for cartilage cell differentiation in mesenchymal stem cells (MSCs), and provides a promising method for regenerative cartilage therapy. By treatment with Avn C, MSCs exhibit enhanced cartilage cell differentiation and increased expression of critical specific cartilage forming extracellular matrix (ECM) factors, especially collagen type II (COL2A1). Furthermore, when Avn C is used in combination with chondroitin sulfate (CS), synergy is observed, resulting in an upregulation of the transcriptional activity state of the key regulatory factor SOX9 of cartilage formation. According to the invention disclosed by the invention, the mRNA gene expression (ACAN, LRP1 and SOX9), the cell protein level (COL2A1, SOX9 and LRP1) and the functional result are obviously improved, for example, the secretion of extracellular matrix proteins (FSTL-1, BGH3, CO1A1, CO1A2 and CO3A1) is proved.
Need to check novelty before this filing date? Find Prior Art